Member Info for Countach

Cash is cash, all businesses use cash to invest and operate. Sitting on 20m is a whole lot better than eating into a credit facility like many other companies are doing.

Yes, that money is going into supporting Creo as its user base grows.

That is the significant point. The user base is growing and at a good pace.

Creo is a company that is now moving from a development plan to a commercial one.

As I say, we all look at these things from different view points.

I was starting to get frustrated myself with the management a year or so ago. However, the updated board have the bull by the horns.

The current SP reflects a market wanting to see further progress.

Once it does you won't be buying at this price again.

Question is, do you think the user base will continue to grow?

I'd dispute your take on the value.

Current cash and the 49% stake is at least equal to the current market cap.

Therefore you are buying creo core and all it's possibilities for free right now.

We all see things differently, to me the potential is enormous and at effectively zero cost right now.

A lot of progress has been made in the past year.

Overhead reduction, poor management practices stamped out. Growth in core product creating a spring board.

For those who want it all to happen tomorrow look elsewhere. The price though won't stay low so you pay your money and take your choice.

Creo are now going in the right direction, not just the increase in core revenue. Important for me is the reporting and actions are more business like.

I put this down to the the current chair who has a lot of skin in the game.

Not much talk yet on 2026 but if the momentum continues it will finally come good.

At 30p i'll make about 14k. If it goes through.

Not as much as I would have liked given the time scale and risk.

I feel though for others. It has a class action written all over it to me.

So Wood has been mismanaged since at least 2017. If losing money why an earth did they turn down the original offer?

Did the board not look at their own accounts?

They have well and truly shafted the share holders, creditors and a once successfull business.

Now the board will walk with a nice payout.

Crazy and unforgivable.

Creo is flashing take over target in my opinion.

Although I 'd rather that interest show after the SP is over 30p than based on the current underpricing.

To me the trading update shows they have turned a very important corner.

Not just because they are now moving from the development stages to roll out, its because the chair has clearly made an impact and showing good business sense.

I think we all agree that prior it was pigs at the trough with too little cost control and sales focus.

Now I have full confidence this going to keep getting better.

US interest will be because intuitive could either sign up to a long-term purchasing deal with Creo or even make an offer.

This one has legs I feel. Huge market potential.

Stock invest technical forecast for Creo

The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at 12.40p is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 33.30% during the next 3 months and, with a 90% probability hold a price between 16.53p and 23.88p at the end of this 3-month period.

This is a seed in more ways than in name.

You plant a seed, you water it and it grows.

People who moan over cssh raises or that the seed is not a tree within a year are in the wrong game.

This will grow and patience will reward.

Channel 4 news tonight. Interview with a surgeon talking about the benefits and huges saving using robotic surgery.

All feeds through for Creo

I bought more again at todays bargain price.

Worth 30p+ in my view

CRISM Therapeutics Corporation

(“CRISM”, “CRISM Therapeutics” or the “Company”)

Best Paper Award

Third party validation for ChemoSeed

CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs, is pleased to announce it has been selected to receive the Drug Delivery and Translational Research Journal Outstanding Paper Award by the Controlled Release Society (“CRS”) for its paper “Local administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumour recurrence in a glioblastoma tumour model”.

The award, co-sponsored by CRS and Springer, recognises the most impactful and innovative original research article published in Drug Delivery and Translational Research during the past year. CRISM’s winning paper, presents foundational research and preclinical validation for ChemoSeed, CRISM’s proprietary localised chemotherapy delivery technology designed to maximise on-target efficacy while minimising systemic toxicity. It highlights ChemoSeed’s translational potential as a safe and effective treatment for glioblastoma.

The award was selected by a panel of internationally recognised scientists and will be formally presented at the upcoming CRS Annual Meeting, taking place in Philadelphia, PA in July 2025.

Prof. Chris McConville, Chief Scientific Officer at CRISM and lead author of the paper, commented:

“We are honoured to receive this recognition from CRS, a global authority in drug delivery science. This award not only reflects the quality of our research but provides strong third-party validation of the scientific underpinnings of ChemoSeed. It reinforces the promise of our platform to deliver targeted, sustained therapeutic action directly at the tumour site in glioblastoma patients. This accolade highlights the innovative potential of ChemoSeed and its ability to redefine treatment delivery for solid tumours. It is a testament to our team's commitment to advancing safer, more effective therapies.”

The full article is available in the February 2024 issue of Drug Delivery and Translational Research, published by Springer and at the following link https://link.springer.com/article/10.1007/s13346-024-01524-x

-Ends-

I bought more today while they had a pause for breath.

If the chair is still buying it tells you something of note.

Many feel the US has peaked. Nothing positive coming from between Trumps ears.

That will mean more buyers scanning other markets.

Only if something is certain rather than believed is it insider trading.

Its pretty obvious now though the ball is picking up pace

A bit of pull back was on the cards considering the good run they have had.

I know figures of 70p+ are out there, which given enough time I do expect due to the market potential.

However, I think back up to 30p could happen without warning and I want to be fully in when it does.

I have a feeling news will be more regular now than it has been.

A commitment for a partnership, notable order or trial update could drop at any point going forward.

Be prepared for the long game but also for unexpected progress.

I often take profits with the aim of buying again on the pullback.

I am not risking that strategy here, I have a target price which is many times higher and sticking to it.

I expect a bit of profit taking this morning so a pause before it gets going again.

Maybe a buying opportunity for those not in.

RNS this morning

https://www.londonstockexchange.com/news-article/CREO/us-reimbursement-milestone-for-speedboat-procedure/17056584